Publications and communications of JASPERS, Aurélie

Rijneveld, A. W., van der Holt, B., de Weerdt, O., Biemond, B. J., Van de Loosdrecht, A. A., van der Wagen, L. E., Bellido, M., van Gelder, M., van der Velden, W. J. F. M., Selleslag, D., van Lammeren-Venema, D., Halkes, C. J. M., Fijnheer, R., Havelange, V., Sluis, G. V., Legdeur, M.-C. J. C., Deeren, D. H., Gadisseur, A. P., Sinnige, H. A. M., & Cornelissen, J. J. (In press). Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial. Blood Advances. doi:10.1182/bloodadvances.2021005624

BAYOUDH, F., JASPERS, A., Azerad, M.-A., SOMJA, J., Marechal, H., & Beguin, Y. (2022). A rare case of massive myocardial infiltration by a disseminated extra-nodal NK/T-cell lymphoma. EJHaem.

DE VOEGHT, A., JASPERS, A., BEGUIN, Y., Baron, F., & DE PRIJCK, B. (2021). Principes généraux de la prise en charges des leucémies aiguës de l’adulte en 2021 en Belgique. Revue Médicale de Liège, 76, 470-475.

Janssen, J., Löwenberg, B., Manz, M., Bargetzi, M., Biemond, B., Borne, P. V. D., Breems, D., Brouwer, R., Chalandon, Y., Deeren, D., Efthymiou, A., Gjertsen, B.-T., Graux, C., Gregor, M., Heim, D., Hess, U., Hoogendoorn, M., JASPERS, A., Jie, A., & Ossenkoppele, G. (2021). Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers, 13, 672. doi:10.3390/cancers13040672

PIROTTE, M., Fillet, M., SEIDEL, L., JASPERS, A., Baron, F., & Beguin, Y. (2021). Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant. American Journal of Hematology, 96 (10), 1275-1286. doi:10.1002/ajh.26300

Ossenkoppele GJ., Breems DA., Stuessi G., van Norden Y., Bargetzi M., Biemond BJ., von dem Borne, P. A., Chalandon Y., Cloos J., Deeren D., Fehr M., Gjertsen B., Graux C., Huls G., Janssen JJJW., JASPERS, A., Jongen-Lavrencic M., de Jongh E., Klein SK., & Löwenberg, B. (July 2020). Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. Leukemia, 34, 1751-1759. doi:10.1038/s41375-020-0725-0

Van Severen, C., JASPERS, A., Weber, T., & Gustin, M. (July 2020). Lymphohistiocytose hémophagocytaire sur réactivation de l’Epstein-Barr Virus. Revue Médicale de Liège, 75(7-8), 512-517.

Azerad, M.-A., BAYOUDH, F., Weber, T., Minon, J.-M., Ketelsleggers, O., HOYOUX, M., Ren, X., Kaye, O., De Marneffe, N., Fraipont, V., Masset, C., Bouillon, A.-S., JASPERS, A., Tebache, M., D'Hoen, G., Habibi, A., Efira, A., Thachil, J., Deckmyn, H., & BEGUIN, Y. (2020). Sickle cell disease and COVID-19: Atypical presentations and favorable outcomes. EJHaem, 1 (jha 2.74), 338-341. doi:10.1002/jha2.74

Antoine-Poirel, H., Vanspauwen, M., Macq, G., De Geyndt, A., Maertens, J., WILLEMS, E., Selleslag, D., Poiré, X., Theunissen, K., Graux, C., Kerre, T., Zachée, P., Meuleman, N., De Becker, A., Verlinden, A., Van Obbergh, F., Schuermans, C., De Wilde, V., JASPERS, A., & Beguin, Y. (2019). Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres. Bone Marrow Transplantation, 54, 1434-1442. doi:10.1038/s41409-019-0458-8

JASPERS, A., & Beguin, Y. (2019). Erythropoiesis and iron metabolism after hematopoietic stem cell transplantation. Belgian Journal of Hematology, 10, 89-95.

SID, S., Baron, F., WILLEMS, E., Caers, J., Bonnet, C., DE PRIJCK, B., LEJEUNE, M., HAFRAOUI, K., Servais, S., JASPERS, A., & Beguin, Y. (November 2016). Hematologic recovery after autologus stem cell transplantation in multiple myeloma: a single center experience of 225 patients. Paper presented at 16ème Congrès commun de la SFGM-TC & 8ème de la SFBCT, Liège, Belgium.

JASPERS, A., Bouhya, S., Belaiche, S., Chevallier, P., Hermet, E., Hospital-Gustems, C., Michallet, M., Rialland, F., Samsonova, O., Sirvent, A., Yakoub-Agha, I., Rohrlich, P.-S., & BEGUIN, Y. (2016). Evaluation et prise en charge de la surcharge en fer post-greffe recommandations de la SFGM-TC. Bulletin du Cancer, 103, 255-S266. doi:10.1016/j.bulcan.2016.09.003

JASPERS, A. (2015). Erythropoiesis and iron metabolism after hematopoietic stem cell transplantation. Unpublished doctoral thesis, ULiège - Université de Liège.
Jury: BEGUIN, Y. (Promotor), GOTHOT, A., Delwaide, J., MALAISE, M., BOSLY, A., MICHALLET, M., & BARON, F.

JASPERS, A., Baron, F., SERVAIS, S., LEJEUNE, M., WILLEMS, E., SEIDEL, L., HAFRAOUI, K., Bonnet, C., & Beguin, Y. (September 2015). Erythropoietin therapy after allogeneic hematopoietic cell transplantation has no impact on long-term survival. American Journal of Hematology, 90 (9), 197-199. doi:10.1002/ajh.24100

JASPERS, A., Baron, F., Maertens, J., DE PRIJCK, B., Schots, R., Bonnet, C., HAFRAOUI, K., WILLEMS, E., SERVAIS, S., FILLET, G., & Beguin, Y. (July 2015). Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation [letter to the editor]. American Journal of Hematology, 90 (7), 133-4. doi:10.1002/ajh.24013

JASPERS, A., BARON, F., MAERTENS, J., DE PRIJCK, B., SCHOTS, H., BONNET, C., HAFRAOUI, K., WILLEMS, E., SERVAIS, S., FILLET, G., & BEGUIN, Y. (December 2014). Long-term safety follow-up of a rendomized trial of Darbepoetin Alpha and intravenous iron following autologous hematopoietic cell transplantation. Blood, 124 (21), 3948.

JASPERS, A., Baron, F., WILLEMS, E., Seidel, L., Wiegerinck, E. T., Swinkels, D. W., & BEGUIN, Y. (March 2014). Serum hepcidin following autologous hematopoietic cell transplantation : an illustration of the interplay of iron status, erythropoiesis and inflammation [letter to the editor]. Haematologica, 99 (3), 35-37. doi:10.3324/haematol.2013.100032

Beguin, Y., & JASPERS, A. (2014). Iron sucrose - characteristics, efficacy and regulatory aspects of an established treatment of iron deficiency and iron-deficiency anemia in a broad range of therapeutic areas. Expert Opinion on Pharmacotherapy, 15, 2087-2103. doi:10.1517/14656566.2014.953928

JASPERS, A., Baron, F., WILLEMS, E., HAFRAOUI, K., Bonnet, C., & Beguin, Y. (2014). Long-term survival in patients receiving rhEPO following allogeneic hematopoietic cell transplantation. Belgian Journal of Hematology, 14.

JASPERS, A., Baron, F., WILLEMS, E., HAFRAOUI, K., Vanstraelen, G., Bonnet, C., & Beguin, Y. (2014). Erythropoietin therapy after allogeneic hematopoietic cell transplantation : a prospective randomized trial. Blood, 124, 33-41. doi:10.1182/blood-2014-01-546333

JASPERS, A., CAERS, J., LE GAC, G., FEREC, C., BEGUIN, Y., & FILLET, G. (February 2013). A novel mutation in the CUB sequence of matriptase-2 (TMPRSS6) is implicated in iron-resistant iron deficiency anaemia (IRIDA). British Journal of Haematology, 160 (4), 564-565. doi:10.1111/bjh.12147

BEGUIN, Y., Maertens, J., DE PRIJCK, B., Schots, R., Seidel, L., BONNET, C., HAFRAOUI, K., WILLEMS, E., Vanstraelen, G., SERVAIS, S., JASPERS, A., FILLET, G., & BARON, F. (2013). Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation : A prospective multicenter randomized trial. American Journal of Hematology, 88, 990-996. doi:10.1002/ajh.23552

JASPERS, A., Baron, F., WILLEMS, E., HAFRAOUI, K., Vanstraelen, G., Bonnet, C., & Beguin, Y. (2013). Erythropoietin therapy after allogeneic hematopoietic cell transplantation : a prospective randomised trial. Belgian Journal of Hematology, 16.

Jaspers, A., Baron, F., Bonnet, C., De Prijck, B., Fassotte, M.-F., & Beguin, Y. (2010). Le lymphome du manteau. Revue Médicale de Liège, 65, 171-176.